# US 2012/0252865 A1 · Carbamate derivatives in particular for the treatment of neurological disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252865 A1
- Document ID: US20120252865A1
- Status: Published application
- Kind: A1
- Application number: 13/202,133
- Filed: 2010-03-08
- Published: 2012-10-04
- Earliest claimed: 2009-03-18
- Assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
- Inventors: Walter Cabri; Patrizia Minetti; Giuseppe Campiani; Stefania Butini
- Web page: https://patentgrep.com/patent/US20120252865A1

## CPC

- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 19/00: Drugs for skeletal disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/22: Anxiolytics
- A61P 27/02: Ophthalmic agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 307/56: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 333/26: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to new carbamate derivatives of formula I, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of neurological disorders, such as neuropathic pain and anxiety.

## Claims

### Claim 1

A compound having the general formula I
wherein,
R1 is H, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, (C1-C6)-alkyl substituted with aryl or (C2-C5)-alkynyl;
X is C or N;
Y is CH, O or S;
R2 is H or (C1-C4)-alkyl;
E is NR3R4 or OR5;
R3 and R4, the same or different are H or (C2-C6)-alkyl optionally substituted with aryl;
R5 is (C2-C6)-alkyl optionally substituted with aryl or with (C2-C5)-alkynyl;
wherein the cycle containing the radicals X and Y is a heteroaromatic ring;
its optically active forms such as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof;
with the proviso that when X is N, Y is CH.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein R1 is (C1-C6)-alkyl substituted with aryl or (C2-C5)-alkynyl.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R3 and R4 are H.

### Claim 4 (depends on 1)

The compound according to claim 1, selected from the group consisting of: butyl-carbamic acid 3-(3-carbamoyl-pyrrol-1-yl)-phenyl ester, undec-10-ynyl-carbamic acid 3-(3-carbamoyl-pyrrol-1-yl)-phenyl ester, cyclohexyl-carbamic acid 3-(3-carbamoyl-pyrrol-1-yl)-phenyl ester, (6-phenyl-hexyl)-carbamic acid 3-(3-carbamoyl-pyrrol-1-yl)-phenyl ester, butyl-carbamic acid 3-(3-carbamoyl-5-methyl-furan-2-yl)-phenyl ester, (6-phenyl-hexyl)-carbamic acid 3-(3-carbamoyl-5-methyl-furan-2-yl)-phenyl ester, (6-phenyl-hexyl)-carbamic acid 3-(3-carbamoyl-5-methyl-thiophen-2-yl)-phenyl ester, cyclohexyl-carbamic acid 3-(4-carbamoyl-5-methyl-furan-2-yl)-phenyl ester, (6-phenyl-hexyl)-carbamic acid 3-(4-carbamoyl-5-methyl-furan-2-yl)-phenyl ester, 2-(3-butylcarbamoyloxy-phenyl)-5-methyl-furan-3-carboxylic acid ethyl ester, 1-(3-butylcarbamoyloxy-phenyl)-1H-pyrrole-3-carboxylic acid undec-10-ynyl ester, 1-(3-butylcarbamoyloxy-phenyl)-1H-pyrrole-3-carboxylic acid 6-phenyl-hexyl ester, cyclohexyl-carbamic acid 3-(3-carbamoyl-5-methyl-furan-2-yl)-phenyl ester and cyclohexyl-carbamic acid 3-(3-carbamoyl-5-methyl-thiophen-2-yl)-phenylester.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

Method of treating a pathological state comprising
administering to a patient in need thereof an effective amount of compounds according to claim 1, for the treatment of a pathological state chosen from the group consisting of a neurological disorder, disease of energy metabolism, cardiovascular and respiratory disorders,
gastrointestinal and liver disorders, retinopathy, cancer and musculoskeletal disorders, and
treating said patient of said pathological state.

### Claim 8 (depends on 7)

Method according to claim 7 where the disorder is a neurological disorder.

### Claim 9 (depends on 8)

Method according to claim 8 where the disorder is anxiety.

### Claim 10 (depends on 8)

Method according to claim 8 where the disorder is neuropathic pain.

### Claim 11 (depends on 8)

Method according to claim 8 where the disorder is Parkinson's disease.

### Claim 12 (depends on 1)

A pharmaceutical composition containing at least one compound according to claim 1 as the active ingredient in mixtures with at least one pharmaceutically acceptable vehicle and/or excipient.

### Claim 13 (depends on 1)

A method for inhibiting FAAH comprising the step of administering to a mammal afflicted with a pathological state for which the modulation of FAAH activity would result at improving the health of the patient, an effective amount of a compound of claim 1.

### Claim 14 (depends on 1)

A process for synthesizing compounds of claim 1 comprising reacting compound of formula II
wherein
X is C or N;
Y is CH, O or S;
R2 is H or (C1-C4-alkyl
E is NR3R4 or OR5;
R3 and R4, the same or different are H or (C2-C6)-alkyl optionally substituted with aryl;
R5 is (C2-C6)-alkyl optionally substituted with aryl or with (C2-C5)-alkynyl;
wherein the cycle containing the radicals X and Y is a heteroaromatic ring;
its optically active forms such as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof;
with the proviso that when X is N, Y is CH,
with compounds of formula III
R1—N═C═O Formula III
wherein R1 is H, (C1-C4)-alkyl, (C3-C6)-cycloalkyl, (C1-C6)-alkyl substituted with aryl or (C2-C5),
in a polar solvent in the presence of a base such as NEt3.

### Claim 15 (depends on 1)

A process for preparing a pharmaceutical composition comprising bringing a compound according to claim 1 and a pharmaceutically acceptable vehicle and/or excipient into intimate admixture.

### Claim 16 (depends on 7)

Method according to claim 7, wherein said effective amount comprises from 0.01 mg/kg to 100 mg/kg.

### Claim 17 (depends on 16)

Method according to claim 16, wherein said effective amount comprises from 0.05 mg/kg to 50 mg/kg.
